T cell chemo-vaccination effects after repeated mucosal shiv exposures and oral pre-exposure prophylaxis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Kersh, Ellen N ^a   Adams, Debra R ^a   Youngpairoj, Ae S ^a   Luo, Wei ^a   Zheng, Qi ^a   Cong, Mian er ^a   Aung, Wutyi ^a   Mitchell, James ^a   Otten, Ron ^a   Hendry, R Michael ^a   Heneine, Walid ^a   McNicholl, Janet ^a   Garcia Lerma, J Gerardo ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE SF162P3 VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; CYTOKINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPITOPE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MALE; MEMORY CELL; NONHUMAN; OUTCOME ASSESSMENT; PROPHYLAXIS; RHESUS MONKEY; T LYMPHOCYTE; VACCINATION; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; MACACA MULATTA; MUCOSA; ORAL DRUG ADMINISTRATION; PATHOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ADMINISTRATION, ORAL; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; DEOXYCYTIDINE; DRUG COMBINATIONS; EPITOPES; MACACA MULATTA; MALE; MUCOUS MEMBRANE; ORGANOPHOSPHORUS COMPOUNDS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 79955590703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019295     Document Type: Article

References (35)

1. Willyard C, (2009) A preemptive strike against HIV. Nat Med 15: 126-129.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
3. Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W, (2010) Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci 31: 74-81.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
5. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, et al. (2001) New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 79: 3-13.
6. Kulkarni PS, Butera ST, Duerr AC, (2003) Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 5: 87-103.
7. Tasca S, Tsai L, Trunova N, Gettie A, Saifuddin M, et al. (2007) Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure. Virology 367: 196-211.
8. Buge SL, Ma HL, Amara RR, Wyatt LS, Earl PL, et al. (2003) Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses 19: 891-900.
9. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, et al. (2004) Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A 101: 13026-13031.
10. Otten RA, Adams DR, Kim CN, Jackson E, Pullium JK, et al. (2005) Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 191: 164-173.
11. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194: 904-911.
12. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28.
13. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, et al. (2009) Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83: 10358-10365.
14. Cong ME, Youngpairoj A, Zheng Q, Aung W, Mitchell J, et al. (2010) Complete protection against rectal transmission of an emtricitabine (FTC)-resistant SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. Meeting report, International HIV & Hepatitis Virus drug resistance workshop, supplement to Antiviral Therapy.
15. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, et al. (2008) Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 5: e157; discussion e157.
16. Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, et al. (2010) Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2: 14ra14.
17. Kersh EN, Luo W, Adams DR, Srinivasan P, Smith JM, et al. (2009) Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model. AIDS Res Hum Retroviruses 25: 905-917.
18. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
19. Lifson JD, Rossio JL, Piatak M Jr, Parks T, Li L, et al. (2001) Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 75: 10187-10199.
20. Loffredo JT, Sidney J, Bean AT, Beal DR, Bardet W, et al. (2009) Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol 182: 7763-7775.
21. Ahlers JD, Belyakov IM, (2010) Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115: 1678-1689.
22. Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, et al. (2007) Pol-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J Virol 81: 11703-11712.
23. Martins MA, Wilson NA, Reed JS, Ahn CD, Klimentidis YC, et al. (2010) T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 84: 4352-4365.
24. Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, et al. (2008) Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog 4: e1000185.
25. Promadej N, Costello C, Wernett MM, Kulkarni PS, Robison VA, et al. (2003) Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis 187: 1053-1063.
26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
27. Promadej-Lanier N, Srinivasan P, Curtis K, Adams DR, Kim C, et al. (2008) Systemic and mucosal immunological responses during repeated mucosal SHIV(162P3) challenges prior to and following infection in pigtailed macaques. Virology 375: 492-503.
28. Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, et al. (1998) Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 14: 761-773.
29. Kersh EN, Luo W, Adams DR, Mitchell J, Garcia-Lerma JG, et al. (2008) Short Communication: No Evidence of Occult SHIV Infection as Demonstrated by CD8(+) Cell Depletion after Chemoprophylaxis-Induced Protection from Mucosal Infection in Rhesus Macaques. AIDS Res Hum Retroviruses 24: 543-546.
30. Williams MA, Ravkov EV, Bevan MJ, (2008) Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 28: 533-545.
31. Mueller SN, Ahmed R, (2008) Lymphoid stroma in the initiation and control of immune responses. Immunol Rev 224: 284-294.
32. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, et al. (2001) Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75: 1990-1995.
33. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C, (1999) Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284: 816-819.
34. Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS, (2007) Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). Virology 363: 36-47.
35. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, et al. (2004) Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 189: 1785-1792.